Lexicon Q1 ’17 Earnings Update
Lexicon hosted its Q1 earnings call and provided updates to their T1DM and T2DM diabetes development programs for sotagliflozin and LX2761.
This content is for Read Less members only.
Already a member? Log in here
Category Archives: Topics
Lilly Q1 ’17 Earnings Update
Lilly hosted its Q1 ’17 earnings call and provided an update to its diabetes portfolio including pipeline and LCM activities.
This content is for Read Less members only.
Already a member? Log in here
Lilly Initiates Ph1 for New OAD
A Lilly sponsored Ph1 ClinicaTrials.gov record has been observed for LY3325656. According to the record, the compound is dosed orally and is being compared to liraglutide and in combination with sitagliptin. MOA for LY3325656 remains to be determined.
This content is for Read Less members only.
Already a member? Log in here
J&J Q1 ’17 Earnings Update
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.
This content is for Read Less members only.
Already a member? Log in here
Invokana CKD Outcomes Trial (CREDENCE) Primary Completion Date Delayed
The ClincalTrials.gov record for the CREDENCE trial has been updated to reflect a later primary completion date. The estimated primary completion date has been pushed back from February 11, 2019 to June 28, 2019, which may be due to trial recruitment.
This content is for Read Less members only.
Already a member? Log in here
Merck’s Januvia Receives CRL from FDA for TECOS
Merck has announced it received a complete response letter (CRL) regarding its submission of data from the TECOS cardiovascular outcomes trial for Januvia (sitagliptin). The company has not disclosed the reason for the CRL, but said it is working with FDA to discuss next steps.
This content is for Read Less members only.
Already a member? Log in here
Lilly Increases Diabetes Manufacturing Investment in 2017
Lilly has announced intentions to invest $850M in its US operations in 2017 including $85M to expand the Trulicity device assembly operations. Additionally, Lilly announced the dedication of a $140M insulin cartridge facility.
This content is for Read Less members only.
Already a member? Log in here
Lilly Partners with Sansum for Diabetes Research in the Latino Population
Lilly and the William Sansum Diabetes Center in Santa Barbara, California have entered into a research collaboration to further understand the unmet needs related to diabetes in the Latino population.
This content is for Read Less members only.
Already a member? Log in here
MannKind Sponsors Reality TV Show
In an effort to increase diabetes awareness, MannKind and Bella & Elle Media LLC are collaborating on “Reversed,” a “Diabetes Reality TV Show” to air on Discovery Life Channel in the summer of 2017.
This content is for Read Less members only.
Already a member? Log in here
Lexicon Q4 ’16 Earnings Update
Lexicon hosted its Q4 and full-year 2016 earnings call and provided an update to its diabetes pipeline.
This content is for Read Less members only.
Already a member? Log in here